Osteoporosis and fracture risk evaluation and management: Shared decision making in clinical practice

JAMA - Journal of the American Medical Association

Volumn 317, Issue 3, 2017, Pages 253-254

  Watts, Nelson B ^a   Manson, Jo Ann E ^b,c  

^a Mercy Health Osteoporosis and Bone Health Services   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCIUM; DENOSUMAB; PHOSPHATE; RALOXIFENE; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CALCIUM INTAKE;

BONE DENSITY; BONE STRENGTH; BREAST CANCER; CANCER RISK; CONSULTATION; CYCLING; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE; LIVER DISEASE; MULTIPLE MYELOMA; OSTEOLYSIS; PATIENT CARE; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SHARED DECISION MAKING; SPINE FRACTURE; SWIMMING; WALKING; WEIGHT BEARING; ADMINISTRATION AND DOSAGE; AGE; AGED; BLOOD; CALCIUM INTAKE; COMPLICATION; DECISION MAKING; DIAGNOSTIC IMAGING; DRUG THERAPY; FEMALE; FRACTURES, BONE; MALE; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHOTON ABSORPTIOMETRY; RESISTANCE TRAINING; RISK ASSESSMENT;

ABSORPTIOMETRY, PHOTON; AGE FACTORS; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; CALCIUM, DIETARY; DECISION MAKING; EXERCISE; FEMALE; FRACTURES, BONE; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RESISTANCE TRAINING; RISK ASSESSMENT;

EID: 85010637641     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.19087     Document Type: Review

References (10)

1. Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254-262.
2. Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015; 90(1):53-62.
3. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(7):2359-2381.
4. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis?2016. Endocr Pract. 2016;22(suppl 4):1-42.
5. Fracture risk assessment tool web page. http://www.shef.ac.uk/FRAX/tool.aspx?country=9. Accessed December 6, 2016.
6. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: a report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
7. McClungMR. Cancel the denosumab holiday. Osteoporos Int. 2016;27(5):1677-1682.
8. AACE/ACE osteoporosis patient decision tool. http://empoweryourhealth.org/sites/all/files/AACE-Osteoporosis-Decision-Aid-B.pdf. Accessed December 6, 2016.
9. Wozniak LA, Johnson JA,McAlister FA, et al. Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment. Osteoporos Int. doi:10.1007/s00198-016-3693-5
10. Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res. 2016;31(8):1485-1487.